文献速递流行病学与生物统计医学教育与科研方法

抑郁与自杀风险筛查:美国预防服务工作组更新版证据报告与系统综述

Depression and Suicide Risk Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2023-01-01

本系统综述纳入105项抑郁研究(32项原始研究,N=385607;73项系统综述)和27项自杀风险研究(n=24826),评估初级保健中抑郁与自杀风险筛查及治疗的获益与危害。抑郁筛查与6至12个月后抑郁或临床重要抑郁症状患病率降低相关(合并OR 0.60,95%CI 0.50-0.73;8项RCT,n=10244;I²=0%),多种筛查工具准确性良好;自杀风险筛查证据存在重要空白。

要点

  • 抑郁筛查干预与6至12个月后抑郁或临床重要抑郁症状患病率降低相关(合并OR 0.60,95%CI 0.50-0.73;I²=0%)。
  • 9项患者健康问卷 cutoff≥10 时合并敏感度0.85(95%CI 0.79-0.89)、特异度0.85(95%CI 0.82-0.88)。
  • 第二代抗抑郁药绝对自杀尝试风险小幅增加(OR 1.53,95%CI 1.09-2.15;用药者0.7% vs 安慰剂0.3%)。

核心结论

  • 证据支持在初级保健机构进行抑郁筛查,包括妊娠期和产后。
  • 初级保健机构自杀风险筛查证据存在众多重要空白。

研究设计与样本

  • 系统综述检索MEDLINE、PsychINFO、Cochrane library至2022年9月7日,并监测文献至2022年11月25日。
  • 纳入英文筛查或治疗与对照比较的研究,或筛查工具准确性研究;抑郁工具预先选定,自杀风险工具全部纳入。
  • 一名研究者提取数据、第二名核对准确性,两名研究者独立评价研究质量,证据充分时对原始研究进行Meta分析。

主要发现

  • 抑郁筛查干预(许多包含筛查以外的附加组分)与6至12个月后抑郁或临床重要抑郁症状患病率降低相关(合并OR 0.60,95%CI 0.50-0.73;8项RCT,n=10244;I²=0%)。
  • 9项患者健康问卷 cutoff≥10 时合并敏感度0.85(95%CI 0.79-0.89)、特异度0.85(95%CI 0.82-0.88)(47项研究,n=11234)。
  • 第二代抗抑郁药自杀尝试绝对风险小幅增加(OR 1.53,95%CI 1.09-2.15;n=40857;用药者0.7% vs 安慰剂0.3%;中位随访8周)。
  • 一项自杀风险筛查干预RCT(n=443)发现筛查与未筛查的初级保健患者2周后自杀意念无差异;3项自杀风险工具准确性研究均未重复验证任何工具。

关键数值与推荐

  • 9项患者健康问卷 cutoff≥10:合并敏感度0.85(95%CI 0.79-0.89),特异度0.85(95%CI 0.82-0.88)。
  • 抑郁筛查干预合并OR 0.60(95%CI 0.50-0.73),I²=0%。
  • 第二代抗抑郁药自杀尝试OR 1.53(95%CI 1.09-2.15),用药者0.7% vs 安慰剂0.3%。

临床怎么用

  • 证据支持在初级保健机构进行抑郁筛查,包括妊娠期和产后。
  • 初级保健机构自杀风险筛查证据存在众多重要空白。
  • 原文未据此给出具体临床推荐。

局限性

  • 初级保健机构自杀风险筛查证据存在众多重要空白。
  • 三项自杀风险工具准确性研究均未重复验证任何工具。
  • 纳入的自杀预防研究普遍未显示优于常规照护(常规照护通常包括精神专科治疗)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depression is common and associated with substantial burden. Suicide rates have increased over the past decade, and both suicide attempts and deaths have devastating effects on individuals and families. OBJECTIVE: To review the benefits and harms of screening and treatment for depression and suicide risk and the accuracy of instruments to detect these conditions among primary care patients. DATA SOURCES: MEDLINE, PsychINFO, Cochrane library through September 7, 2022; references of existing reviews; ongoing surveillance for relevant literature through November 25, 2022. STUDY SELECTION: English-language studies of screening or treatment compared with control conditions, or test accuracy of screening instruments (for depression, instruments were selected a priori; for suicide risk, all were included). Existing systematic reviews were used for treatment and test accuracy for depression. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Findings were synthesized qualitatively, including reporting of meta-analysis results from existing systematic reviews; meta-analyses were conducted on original research when evidence was sufficient. MAIN OUTCOMES AND MEASURES: Depression outcomes; suicidal ideation, attempts, and deaths; sensitivity and specificity of screening tools. RESULTS: For depression, 105 studies were included: 32 original studies (N=385 607) and 73 systematic reviews (including ≈2138 studies [N ≈ 9.8 million]). Depression screening interventions, many of which included additional components beyond screening, were associated with a lower prevalence of depression or clinically important depressive symptomatology after 6 to 12 months (pooled odds ratio, 0.60 [95% CI, 0.50-0.73]; reported in 8 randomized clinical trials [n=10 244]; I2 = 0%). Several instruments demonstrated adequate test accuracy (eg, for the 9-item Patient Health Questionnaire at a cutoff of 10 or greater, the pooled sensitivity was 0.85 [95% CI, 0.79-0.89] and specificity was 0.85 [95% CI, 0.82-0.88]; reported in 47 studies [n = 11 234]). A large body of evidence supported benefits of psychological and pharmacologic treatment of depression. A pooled estimate from trials used for US Food and Drug Administration approval suggested a very small increase in the absolute risk of a suicide attempt with second-generation antidepressants (odds ratio, 1.53 [95% CI, 1.09-2.15]; n = 40 857; 0.7% of antidepressant users had a suicide attempt vs 0.3% of placebo users; median follow-up, 8 weeks). Twenty-seven studies (n = 24 826) addressed suicide risk. One randomized clinical trial (n=443) of a suicide risk screening intervention found no difference in suicidal ideation after 2 weeks between primary care patients who were and were not screened for suicide risk. Three studies of suicide risk test accuracy were included; none included replication of any instrument. The included suicide prevention studies generally did not demonstrate an improvement over usual care, which typically included specialty mental health treatment. CONCLUSIONS AND RELEVANCE: Evidence supported depression screening in primary care settings, including during pregnancy and postpartum. There are numerous important gaps in the evidence for suicide risk screening in primary care settings.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. O'Connor EA, Perdue LA, Coppola EL, et al. Depression and Suicide Risk Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023. PMID: 37338873. doi:10.1001/jama.2023.7787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。